Key Points
- Director Lynn Sebastian Purcell purchased 166,666 CNXU shares at an average price of $3.00, investing approximately $500,000 and increasing the director’s holdings by 5.65% to 3.12 million shares.
- Conexeu Sciences reported a quarterly loss of $0.29 per share, missing the consensus estimate of a $0.10 loss; analysts expect a full-year loss of $0.40 per share.
- CNXU shares opened at $3.29, while analyst sentiment was mixed—one Buy, one Hold and one Sell—with an overall consensus rating of Hold and a $20 target price.
Conexeu Sciences Inc. (NASDAQ:CNXU - Get Free Report) Director Lynn Sebastian Purcell acquired 166,666 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were purchased at an average cost of $3.00 per share, for a total transaction of $499,998.00. Following the completion of the acquisition, the director owned 3,118,514 shares in the company, valued at $9,355,542. This represents a 5.65% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Conexeu Sciences Stock Up 7.5%
NASDAQ:CNXU opened at $3.29 on Tuesday. The stock has a 50 day moving average price of $5.37. The company has a market cap of $92.80 million and a P/E ratio of -8.22. Conexeu Sciences Inc. has a 1-year low of $3.05 and a 1-year high of $18.79.
Conexeu Sciences (NASDAQ:CNXU - Get Free Report) last issued its earnings results on Monday, September 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.19). On average, research analysts anticipate that Conexeu Sciences Inc. will post -0.40 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have recently issued reports on CNXU. Zacks Research raised shares of Conexeu Sciences to a "hold" rating in a research note on Monday, June 29th. HC Wainwright assumed coverage on shares of Conexeu Sciences in a report on Monday, June 22nd. They set a "buy" rating and a $20.00 target price on the stock. Finally, Weiss Ratings began coverage on shares of Conexeu Sciences in a research report on Monday, August 17th. They issued a "sell (e-)" rating on the stock. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Conexeu Sciences has an average rating of "Hold" and a consensus target price of $20.00.
Check Out Our Latest Analysis on Conexeu Sciences
Conexeu Sciences Company Profile
(
Get Free Report)
Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
